A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study

BACKGROUND. Activation of the mitogen-activated protein kinase pathway is important for growth of pediatric low-grade gliomas (LGGs). The aim of this study was to determine the recommended phase II dose (RP2D) and the dose-limiting toxicities (DLTs) of the MEK inhibitor selumetinib in children with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Banerjee, Anuradha, Jakacki, Regina I., Onar-Thomas, Arzu, Wu, Shengjie, Nicolaides, Theodore, Young Poussaint, Tina, Fangusaro, Jason, Phillips, Joanna, Perry, Arie, Turner, David, Prados, Michael, Packer, Roger J., Qaddoumi, Ibrahim, Gururangan, Sridharan, Pollack, Ian F., Goldman, Stewart, Doyle, Lawrence A., Stewart, Clinton F., Boyett, James M., Kun, Larry E., Fouladi, Maryam
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570236/
https://ncbi.nlm.nih.gov/pubmed/28339824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados